Manganese superoxide dismutase, MnSOD and its mimics

Sumitira Miriyala a, Ivan Spasojevic b, Artak Tovmasyan c, Daniela Salvemini d, Zeljko Vujaskovic c, Daret St. Clair a,∗, Ines Batinic-Haberle c,**

a Graduate Center for Toxicology, University of Kentucky, Lexington, KY, 40536, USA
b Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
c Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
d Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO 63104, USA

ARTICLE INFO

Article history:
Received 20 October 2011
Received in revised form 2 December 2011
Accepted 2 December 2011
Available online 9 December 2011

Keywords:
MnSOD mimics
MnSOD
MitoQ
Mn porphyrins
MnTE-2-PyP
MnTriHex-2-PyP

ABSTRACT

Increased understanding of the role of mitochondria under physiological and pathological conditions parallels increased exploration of synthetic and natural compounds able to mimic MnSOD — endogenous mitochondrial antioxidant defense essential for the existence of virtually all aerobic organisms from bacteria to humans. This review describes most successful mitochondrially-targeted redox-active compounds, Mn porphyrins and MitoQ10 in detail, and briefly addresses several other compounds that are either catalysts of O2− dismutation, or its non-catalytic scavengers, and that reportedly attenuate mitochondrial dysfunction. While not a true catalyst (SOD mimic) of O2− dismutation, MitoQ10 oxidizes O2− to O2 with a high rate constant. In vivo it is readily reduced to quinol, MitoQH2, which in turn reduces ONOO− to NO2, producing semi-quinone radical that subsequently dismutes to MitoQ10 and MitoQH2, completing the “catalytic” cycle. In MitoQ10, the redox-active unit was coupled via 10-carbon atom alkyl chain to monocationic triphenylphosphonium ion in order to reach the mitochondria. Mn porphyrin-based SOD mimics, however, were designed so that their multiple cationic charge and alkyl chains determine both their remarkable SOD potency and carry them into the mitochondria. Several animal efficacy studies such as skin carcinogenesis and UVB-mediated mtDNA damage, and subcellular distribution studies of Saccharomyces cerevisiae and mouse heart provided unambiguous evidence that Mn porphyrins mimic the site and action of MnSOD, which in turn contributes to their efficacy in numerous in vitro and in vivo models of oxidative stress. Within a class of Mn porphyrins, lipophilic analogs are particularly effective for treating central nervous system injuries where mitochondria play key role. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

Superoxide (O2−) has a prominent role in oxidative stress and impacts the production of a plethora of other reactive species, such as H2O2, peroxynitrite (ONOO−), peroxynitrite degradation products (OH, NOx, CO2), lipid peroxy (RO2) and alkoxy (RO) radicals. Its one-electron reduction product, H2O2, is a dominant signaling molecule [1]. Endogenous antioxidants maintain reactive species at nanomolar levels, and any increase results in redox imbalance (oxidative stress) [2], which in turn leads to excessive inflammatory and immune responses. The superoxide dismutase family of enzymes is comprised of MnSOD located in the mitochondrial matrix, and CuZnSOD located in the mitochondrial intermembrane space, cytosol and extracellular space. These key enzymes catalyze the dismutation (disproportionation) of superoxide anion radical to hydrogen peroxide and molecular oxygen [2]. In doing so, they protect cells against oxidative damage and regulate the cellular concentration of O2− and its reactive progeny under both physiological and pathological conditions [2]. Mutations in CuZnSOD have been linked to amyotrophic lateral sclerosis, and deficiency of CuZnSOD has been associated with accelerated aging and a higher incidence of cancer [3–6]. However, aerobic life without MnSOD is not sustainable. A substantial body of evidence has been established by Fridovich and his associates [7,8] that MnSOD is ubiquitous metalloenzyme essential for the survival of all aerobic organisms from bacteria to humans. It is even found in many anaerobes where it protects the cell during exposure to aerobic conditions [9]. Cambialistic enzymes are found in several anaerobic bacteria, such as Propionibacterium shermanii, and have either Mn3+ or Fe3+ at their active site. When
growing anaerobically, these enzymes contain Fe$^{3+}$, but when grown under micro aerobic conditions, these enzymes have Mn$^{3+}$ at their active site [10]. MnSOD is encoded by a nuclear gene and is transported across two mitochondrial membranes to the matrix. In humans, the translocation involves translation of a preenzyme which includes a 24-amino acid N-terminal peptide targeting the protein to the mitochondria. In mice, the lack of MnSOD, or the complete elimination of its expression, causes dilated cardiomyopathy and neurodegeneration leading to early postnatal death. These mice exhibit severe oxidative damage to mitochondria and are also extremely sensitive to hyperoxia [11,12]. It has been clearly demonstrated that heterozygous MnSOD knock-out mice have a 50% decrease in MnSOD enzyme activity in all tissues compared to wild-type mice, resulting in an age-dependent increase in oxidative DNA damage (8-hydroxy-2'-deoxyguanosine) in both nucleus and mitochondria.

A critical role of MnSOD under physiological and pathological conditions has recently been reviewed in details by St. Clair’s group [13,14]. Herein, we briefly summarized the role of MnSOD in general, and tumorigenesis in particular. The MnSOD enzyme is involved in maintaining nanomolar, physiological levels of O$_2^−$ and its progeny. In a very elegant and comprehensible report by Buettner et al., a more complex role of MnSOD in establishing cellular redox environment and thus biological state of the cell was discussed based on thermodynamic and kinetic grounds [15,16]. In addition to its traditional role in controlling levels of O$_2^−$ via catalysis of O$_2^−$ dismutation, MnSOD also modulates the accumulation of H$_2$O$_2$ in cells, most so effecting those O$_2^−$-involving reactions whose equilibrium constant is K≈1, such as the production of superoxide from mitochondrial respiration at the site of coenzyme Q [15,16].

Moreover, MnSOD influences the activity of transcription factors (such as HIF-1α, AP-1, NF-kB and p53) and affects DNA stability: an example being the action of overexpressed MnSOD on the maspin (mammary serine protease inhibitor) mRNA in MCF-7 breast cancer cells that results in decreased invasiveness [17]. Further, overexpression of MnSOD affects the activity of HIF-1α in MCF cells in a bi-phasic manner: at lower levels of MnSOD, HIF-1α levels are elevated, but are suppressed at higher MnSOD levels [18]. The bi-phasic influence of MnSOD on activation of HIF-1α is H$_2$O$_2$-dependent, as removal of peroxides reverses the effect [18]. While the same bi-phasic behavior has been observed in IL-1α expression, it has not been observed in the migration potential of HT-1080 cells [19]. Low levels of MnSOD are able to drive migration, and higher levels of MnSOD potentiate the effects. Further, overexpression of MnSOD causes reduction of AP-1 transcriptional activity in MCF-7 cells, which is mediated through altered expression of the Jun family of AP-1 subunits [20]. In a DMBA/TPA skin carcinogenesis model, AP-1 activation was much higher in normal (non-transgenic) mice than in MnSOD overexpressor (transgenic) mice [20]. Overexpression of MnSOD in MCF-7 cells diminishes NF-κB activity and expression of IL-1 and IL-6, both NF-κB responsive genes. MnSOD also modulates the transcriptional activity of p53 [21]. Finally, overexpression of MnSOD impedes aneuploidy in Lck-Bax38/1 mice [22,23]. A recent study by Mesquita et al. on the life-span of Saccharomyces cerevisiae further emphasizes a vital role of MnSOD in cell physiology. When yeast was stressed by caloric restriction or calcine inactivation, and H$_2$O$_2$ levels increased above physiological levels but did not reach toxicity, the yeast tried to adapt via H$_2$O$_2$-induced stress response and upregulated SODs, in particular MnSOD [24]. Similar hormesis effects are suggested to be operative in aging [24]. Similarly, the modulation of O$_2^−$ levels and transcriptional activity observed with MnSOD were detected with Mn porphyrin-based SOD mimics (see below, under Mn porphyrins section).

An early report by Oberer (L.W. and T. D.) and Buettner showed that MnSOD is a tumor suppressor gene in a wide variety of cancers [3–6]. Yet, Hempel et al. have presented data that show increased levels of MnSOD in different tumor types [19]. Additional increase of MnSOD level was found during progression of a tumor to the metastatic stage in head and neck, pancreatic, gastric, colorectal brain, and oral squamous cell carcinomas. Such apparently controversial data likely arise from the differences in the redox status of the tumors explored (Fig. 1). Tumorigenesis and metastasis are strongly dependent on the intrinsic levels of reactive species, as well as external factors that would increase the production of reactive species. A “normal” cell which has low levels of MnSOD is susceptible to oxidative stress, which in turn may favor its progression to a tumor cell [19] (Fig. 1). Further, studies with transgenic mice expressing a luciferase reporter gene under the control of human MnSOD promoter demonstrate that the levels of MnSOD in such already transformed cell were reduced prior to the for-
Evidence from the site-directed mutagenesis studies indicate that His-30 is an important amino acid involved in the hydrogen bond network in the catalytic domain of MnSOD. The proteomic analysis of MnSOD from a medulloblastoma cell line showed the presence of 2-oxo-histidine in His 30 and 31 residues [19]. Another mechanism of MnSOD inactivation is nitration of a protein tyrosine residue [39,40].

A similar observation was recently published with respect to thioredoxin in a low-grade human prostate cancer tissue: though protein levels were increased, the thioredoxin activity was reduced [41]. It is therefore critical that conclusions are always based on both protein expression and its activity.

In summary, the opposing views of MnSOD as tumor suppressor (antioxidant) or oncogene (pro-oxidant) may possibly be reconciled based on the differences in the redox status of normal, transformed, tumor and metastatic cells (Fig. 1). Much remains to be learned about the role of both MnSOD and its mimics under physiological and pathological conditions. For further discussion, see also the Special Issue on "Anti-Cancer Agents in Medicinal Chemistry," on “SOD enzymes and their mimics in cancer: pro- vs anti-oxidative mode of action,” ACAMC, 2011 [14,15,19,28,29].

2. SOD mimics

The essential role of superoxide dismutases in maintaining healthy metabolism and rescuing diseased cells, the rising awareness of the key impact of oxidative stress in numerous diseases, and the essential role of mitochondria in cell metabolism have led to a three-decade long effort to synthesize SOD mimics, particularly those that target MnSOD.

\[
M^{10}P^5^+ + O_2^- \leftrightarrow M^{10}P^5^{++} + O_2
\]  

(1) 

\[
M^{10}P^5^{++} + 2H^- + O_2^- \rightarrow M^{10}P^5^{++} + H_2O_2
\]  

(2) 

mitochondria. The first data appeared in the late 1970s on the ability of Fe porphyrin, FeTM-4-PyP5+, to catalyze O2- dismutation, via a two-step process (Eqs. (1) and (2), where M stands for metal) alike the one operative with SOD enzymes [42]:

It is only logical that the first compound studied as an SOD mimic was a metal complex. With SOD enzymes (FeSOD, MnSOD, NiSOD, Cu,ZnSOD), the catalysis occurs at the redox active metal site, which is able to easily accept and donate electrons and thus oxidize and reduce O2-. Iron porphyrin was the first metalloporphyrin explored, as iron is the active site of numerous enzymes whose functions are redox-based. The examples are the cyt P450 family of enzymes, nitric oxide synthases, cyclooxygenases, and prolylhydroxylases. The reason for utilizing a metalloporphyrin as an active site is the cyclic nature of the porphyrin ligand which forms a metal complex of extreme stability, and thus assures the integrity of the metal site. Exploration of Mn porphyrins followed. Relative to Fe porphyrins, they have been considered more favorable agents for O2- removal, as they preclude the release of “free” iron, which could possibly result in a Fenton-based toxicity. Other metal complexes, such as Mn salen derivatives, Mn cyclic polyamines, metal carboxylates, metal oxides, Pt nanoparticles and non-metal compounds such as nitrones and nitroxides as well as natural products, have also been explored for their ability to catalytically remove O2- (Figs. 2 and 3), and were discussed in details elsewhere [27,43-46]. Among the synthetic compounds, nitrones and nitroxides are not able to catalytically scavenge superoxide, whereas they are able to react with peroxynitrite. The oxoammonium cation, formed during one-electron oxidation of nitroxide, can in turn react with O2-, completing the “catalytic” cycle. Low-molecular Mn complexes with carboxylates have also been explored, as nature utilizes...
manganese as a substitute for superoxide dismutase [47–50]. Further, such studies are valuable because most high-molecular weight Mn complexes could release Mn, when cycling from a stable, higher +3 oxidation state to a less stable lower +2 oxidation state of Mn, during the two steps of a dismutation process. Among high-molecular weight metal complexes, cationic Fe and Mn porphyrins bearing meso cationic pyridyl substituents, appear to have the highest catalytic rate constant for O$_2^-$ dismutation, $k_{cat}(O_2^-)$. Those compounds, which are substituted with electron-withdrawing groups on both $\beta$ and meso positions of porphyrin ring (Figs. 2 and 7), have the highest $k_{cat}$, nearing that of the enzyme itself. The most potent is the Mn(II)$\beta$-octabromo-meso-tetraakis(N-methylpyridinium-3-yl)porphyrin, MnBr$_8$TM-3-PyP$_4^+$ (Fig. 7, Table 1), whose log $k_{cat}$ is $\geq 8.85$, while SOD has the log $k_{cat}$ in between 8.84 and 9.30 [45]. Yet, the complex is unstable as it carries Mn in a lower +2 oxidation state, which has insufficient charge density to bind porphyrin ligand strongly enough. With no $\beta$-substituents, the Mn(III) N-alkylpyridylporphyrins are stable complexes (even in 36% hydrochloric acid), and have a log $k_{cat}$ ranging from 6.58 to 7.79. A comprehensive overview of different classes of SOD mimics has been reported recently [44–46].

3. MnSOD mimics

Increased understanding of the role of mitochondria and its enzyme, MnSOD, has motivated researchers to explore existing and new compounds for their ability to enter mitochondria and mimic MnSOD. This review covers only those compounds that reportedly possess fair SOD-like properties (are catalysts of O$_2^-$ dismutation), or are stoichiometric scavengers of O$_2^-$, and for which evidence exists that they are efficacious in attenuating mitochondrial dysfunction. Mn porphyrins and MitoQ$_{10}$ are addressed in this report in detail, as there is substantial evidence that they accumulate in mitochondria and possess high rate constants for reaction with O$_2^-$. Both types of compounds bear a cationic charge (shown by Liberman, Skulachev
and Murphy to be a driving force for drug accumulation in mitochondria), lipophilic entity and a redox-active unit [51–53]. Singly-charged MitO10 is more lipophilic than either of the pentacationic Mn porphyrins studied; it seems that at least in part, the multiple charge of Mn porphyrins compensates for their much lower lipophilicity. Mn cyclic polyamine-based SOD mimics and the most potent compounds within the class of redox-active corroles lack positive charge or are anionic compounds, respectively; their mitochondrial accumulation would thus be disfavored [46,54]. No evidence has yet been provided that these compounds reach mitochondria.

3.1. MnSOD-plasmid liposome gene

The natural way to compensate for MnSOD is to use MnSOD itself in a bioavailable form — MnSOD-plasmid liposome gene. Such therapy has been shown to decrease irradiation-induced lipid peroxidation of the mouse esophagus [55].

3.2. The attachment of mitochondria-targeted amino acid sequence to a Mn porphyrin-based SOD mimic

Asayama et al. attached a mitochondria-targeted amino acid sequence to a Mn porphyrin-based SOD mimic, MnTM-4-PyP5+ (Fig. 2) [56]. By using the pH-sensitive aminated poly(L-histidine) drug carrier for intracellular delivery, the new conjugate recovered the viability of lipo-polsaccharide (LPS)-stimulated macrophage RAW 264.7 cells.

3.3. Pyrroloquinoline quinone (PQQ)

PQQ (Fig. 3) is a water-soluble redox cycling orthoquinoine, a nutrient widely distributed in nature. It serves as a non-covalently bound redox cofactor in a series of bacterial quinoprotein dehydrogenases and has been explored for treatment of mitochondrial disorders [57]. In the presence of reducants, PQQ scavenges ROS in bacteria [58]. PQQ protects isolated liver mitochondria from oxidative damage, via superoxide scavenging, and was neuroprotective in a rodent stroke model where its action was assigned to peroxynitrite scavenging [57–63]. PQQ also reduces myocardial infarct size, improves cardiac function, and reduces lipid peroxidation as measured by malondialdehyde levels [64,65].

3.4. MnSalens

While not significantly efficacious in a cellular model of ataxia telangiectasia, MnSalen, EUK-8 (Fig. 2) was very efficacious in the protection of the MnSOD-knock out yeast Cryptococcus neoformans against heat-mediated injury [66]. Neither cationic nor anionic Mn porphyrins were efficacious. Also, Tempol and MnCl2 lacked efficacy. EUK-8 is a fairly unstable complex and loses Mn in the presence of EDTA [67]. Therefore, in vivo, MnSalen perhaps serves as a Mn transporter into mitochondria. Cationic Mn(III) N-alkylpyridylporphyrin complexes are too strong to release manganese. MnTBAP− carries a triple negative charge and thus cannot easily reach mitochondria. Furthermore, it is too stable to release Mn there, and is not SOD mimic in its own right [68]. Data on C. neoformans justify further exploration of MnSalen derivatives. Irradiated astrocytes have been shown to develop mitochondrial abnormalities attenuated in a dose-dependent manner by EUK-134. Vorotnikova et al. showed that EUK-207 and EUK-189 inhibit radiation-induced apoptosis in bovine adrenal endothelial cells [69]. A study on life-span extension and rescue of spongiform encephalopathy in MnSOD−/− mice showed that EUK-8 mimics MnSOD; yet, that report has been questioned by Keaney et al. [70,71].

3.5. MnMImP3P2−

The Mn(III) porphyrin, MnMImP3P2−, depicted in Fig. 2, reportedly targets mitochondria [72]. When compared to its fully ethylated tetramethylazol analog MnTET-2-ImP5+, the compound has only one imidazolium ring fully methylated, and thus carries 2 instead of 8 methyl groups. Consequently, MnMImP3P2− bears only 2+ instead of 5+ total charges, has therefore reduced antioxidant potency, but increased lipophilicity relative to MnTET-2-ImP5+ (Table 1). The inferior SOD-like activity of MnMImP3P2− is at least in part compensated by its fair lipophilicity (log POW = 4.78), which in turn favors its mitochondrial accumulation.

3.6. Nitroxides

Nitroxides (Fig. 3) are weak SOD mimics [46]; their SOD activity increases with a pH drop due to their high reactivity with protonated superoxide, HO2− the RNO/RNO− redox couple is involved [46]. Nitroxides, RNO can be oxidized to o xoammonium cation, RNO+ with ONOO− (Table 1), which in turn rapidly reacts with O2− regenerating RNO; thus, the catalytic removal of O2− may be coupled to the reaction
with ONOO\textsuperscript{−}. In vivo nitroxides, RNO are reduced to hydroxyamine, RNOH, which reportedly acts as an antioxidant [73]. The lipophilic ketone analogs, tempepe and oxazolidine-5-doxylstearate (but not hydrophilic tempol), are reduced by mitochondria of intact cells, which indicates the ability of nitroxide to reach these cellular components. While nitroxides are uncharged, nitrones such as PBN carry an anionic charge. Therefore, PBN may localize in mitochondria only after reacting with free radicals, thereby losing its anionic charge [74]. 5,5-dimethyl-1-pyrroline-1-oxide, DMPO, a spin trapping agent, reportedly enters mitochondria, where it is reduced by the electron-transport chain of mitochondria of synaptosomes [75].

3.7. Manganese dipir

A Mn complex with dipyrroloxyl phosphate (Fig. 2), a MRI contrast agent for liver and cardiac imaging, has been shown to improve contractile function and reduce enzyme release in rat heart tissue during reoxygenation, and could be used as a viability marker in patients with myocardial infarction. It has also been shown to reduce mitochondrial damage by reducing reactive species, presumably mimicking superoxide dismutase [76], catalase and glutathione reductase [77].

3.8. Mitochondria-targeted peptide

Other compounds that possess the ability to scavenge reactive species, but that have no SOD-like activity, have also been developed. An example is the mitochondrially-targeted peptide that contains dimethyltyrosine unit (Dmt), which reportedly scavenge reactive species [78,79]. The unique feature of SS-02 (H-Dmt-D-Arg-Phe-Lys)\textsuperscript{−} is its alternating aromatic–cationic structural motif, where aromatic residues (Dmt and Phe) alternate with basic residues (Arg and Lys). This motif allows for intramolecular cation–π interaction between the electron-rich π ring (Dmt or Phe) and the adjacent cation (Arg or Lys). The additional methyl groups on Dmt further increase electron density on the π ring. Cation–π energies are of the same order of magnitude as hydrogen bonding energies, and the π rings may shield the cation charge and enhance membrane penetration. Thus, this aromatic–cationic motif is retained in the design of non-opioid analogs of SS-02. Reactive nitrogen and halogen species, OH and \( \text{RO}_2/\text{RO} \) [80], are known to target tyrosine, thereby producing dihydroxyphenylalanine and tyrosine radicals. Tyrosine radicals would form dityrosine, a reaction that is facilitated by \( \text{O}_2^- \) [81]. While substitution of dimethyltyrosine with phenylalanine resulted in the loss of antioxidant capacity, the peptide was still able to reduce ROS generation [78,79]. It must be noted that formation of tyrosine radicals is usually associated with the oxidative damage of protein [82]. Dimethyltyrosine unit (Dmt), which reportedly scavenges reactive species, but that have no SOD-like activity, have also been developed. An example is the mitochondrially-targeted peptide that contains dimethyltyrosine unit (Dmt), which reportedly scavenges reactive species [78,79]. The unique feature of SS-02 (H-Dmt-D-Arg-Phe-Lys)\textsuperscript{−} is its alternating aromatic–cationic structural motif, where aromatic residues (Dmt and Phe) alternate with basic residues (Arg and Lys). This motif allows for intramolecular cation–π interaction between the electron-rich π ring (Dmt or Phe) and the adjacent cation (Arg or Lys). The additional methyl groups on Dmt further increase electron density on the π ring. Cation–π energies are of the same order of magnitude as hydrogen bonding energies, and the π rings may shield the cation charge and enhance membrane penetration. Thus, this aromatic–cationic motif is retained in the design of non-opioid analogs of SS-02. Reactive nitrogen and halogen species, OH and \( \text{RO}_2/\text{RO} \) [80], are known to target tyrosine, thereby producing dihydroxyphenylalanine and tyrosine radicals. Tyrosine radicals would form dityrosine, a reaction that is facilitated by \( \text{O}_2^- \) [81]. While substitution of dimethyltyrosine with phenylalanine resulted in the loss of antioxidant capacity, the peptide was still able to reduce ROS generation [78,79]. It must be noted that formation of tyrosine radicals is usually associated with the oxidative damage of protein [82].

3.9. Manganese and its complexes with simple ligands

Evidence suggests that MnSalen, EUK-8 and MnBr\textsubscript{5}TM-3-Ppy\textsuperscript{4+} transport Mn into the mitochondria of \( \text{C. neoformans} \) and into the cytosol of \( \text{Escherichia coli} \), respectively [29,82]. One of the hypotheses is that mitochondria of eukaryotic cell have evolved from bacteria [83]. Thus, the data related to the cytosol of prokaryotic \( \text{E. coli} \) are relevant to the mitochondrial matrix of \( \text{C. neoformans} \). In MnSOD-knockout \( \text{C. neoformans} \), MnSalen or the Mn released in mitochondria from its complex has been shown to substitute for the lack of MnSOD (see also under MnSalens section 66). Lactobacillus plantarum accumulates Mn to millimolar levels as a protection against oxidative stress [47]. Expressed per milligram of Mn, the SOD-like activity of Mn(II) lactate is 65-fold lower than that of SOD enzymes [46]. Mn\textsuperscript{2+} protects E. coli when growing aerobically at > 0.5 mM [84], and exogenous Mn millimolar concentrations rescued \( \text{O}_2^- \)-sensitive phenotype of \( \text{S. cerevisiae} \) lacking CuZnSOD [46,50,85,86]. Finally, Mn\textsuperscript{2+} accelerates wild type development, enhances stress resistance and rescues the life span of a short-lived \( \text{Caenorhabditis elegans} \) mutant [87].

4. MitoQ\textsubscript{10}

The Liberman's, Skulachev's and Murphy's groups [49–51] clearly established that both positive charge and lipophilicity play critical roles in a molecule intended for mitochondrial targeting. Thus both features were incorporated into the design of MitoQ\textsubscript{10}. The compound was developed to enter cells driven by plasma membrane potential, and mitochondria driven by mitochondrial membrane potential. In MitoQ, a redox-cycling quinone, an analog of the ubiquinone of the mitochondrial electron transport chain, was coupled to a cationic triphenylphosphonium ion via long lipophilic alkyl chain [89]. The longer the alkyl chain, the higher is the mitochondrial accumulation of MitoQ [89]. An optimized MitoQ\textsubscript{10} molecule, with a 10-carbon atom-alkyl chain, has the capacity to suppress mitochondrial oxidative stress (Fig. 3). In animals and cells, MitoQ\textsubscript{10} is rapidly reduced two-electronically by the mitochondrial respiratory chain to quinol, MitoQH\textsubscript{2}, which is stable over a long-term incubation. The reduction is essential for the compound to act as a reducing agent/antioxidant. The major metabolite detected in vivo is monosulfonated MitoQ\textsubscript{10}, which upon loss of sulfonate regenerates MitoQH\textsubscript{2} [93].

The reactivity of MitoQ\textsubscript{10} toward \( \text{O}_2^- \) and other oxygen radicals has been studied in detail [94]. MitoQ\textsubscript{10} reacts with \( \text{O}_2^- \) in water and methanol with rate constants of 2.0×10\textsuperscript{8} M\textsuperscript{−1} s\textsuperscript{−1} and 4.2×10\textsuperscript{8} M\textsuperscript{−1} s\textsuperscript{−1}, respectively, forming semiquinone radical, MitoQH, which then disproportionate to MitoQ\textsubscript{10} and quinol, MitoQH\textsubscript{2}. Also, MitoQH reacts with \( \text{O}_2^- \) in a reverse reaction with rate constants of 2.9×10\textsuperscript{7} M\textsuperscript{−1} s\textsuperscript{−1} and 7.3×10\textsuperscript{7} M\textsuperscript{−1} s\textsuperscript{−1} in water and methanol, respectively (Fig. 4). The forward reaction is 10-fold more preferred over the backward. The \( \text{E}_{1/2} \) for \( \text{O}_2^-/\text{O}_2 \) couple is −155 mV vs NHE and −630 mV vs NHE in water and aprotic solvents, while it is −105 mV vs NHE and −415 mV vs NHE for the MitoQubisemiquinone in water and UQ/UQH in aprotic solvents, respectively [94]. The reaction of \( \text{O}_2^- \) with MitoQH\textsubscript{2} is insignificant, with a rate constant of \( <10^5 \text{M}^{-1} \text{s}^{-1} \). MitoQH\textsubscript{2} (but not MitoQ quinone), resides in the hydrophobic core of membrane, where it can react with protonated \( \text{O}_2^- (\text{HO}_2^-) \) with a rate constant of \( <10^8 \text{M}^{-1} \text{s}^{-1} \) (Fig. 4). Thus, catalysis of \( \text{O}_2^- \) dismutation may be achieved via coupling of MitoQ\textsubscript{10}/MitoQH\textsubscript{2} with other reactive species and components of the electron-transport chain.

4.1. Reactivities of MitoQ\textsubscript{10} toward other species

MitoQH\textsubscript{2} rapidly reacts with ONOO\textsuperscript{−} (whereby MitoQH\textsubscript{2} is produced, which then undergoes dismutation [89]) and is particularly effective against lipid peroxidation [89]. Similar to other redox-able compounds, MitoQ\textsubscript{10} affects cellular transcriptional activity, presumably by modulating levels of cellular signaling species [53]. It blocks H\textsubscript{2}O\textsubscript{2}-induced apoptosis and cell death, but the mechanism is not fully understood. Further, a partially reduced form of MitoQH\textsubscript{2} (semiquinone) can act as a pro-oxidant. As is the case with Mn porphyrins (see below) and many other redox-active compounds [44,95], MitoQ\textsubscript{10} can act in vivo as a pro-oxidant, which in turn could result in an adaptive response and in upregulation of endogenous antioxidant defenses [89].

4.2. Mitochondrial accumulation of MitoQ\textsubscript{10}

MitoQ\textsubscript{10} distributes predominantly into mitochondria [93]. In both cytosol and mitochondria, MitoQ\textsubscript{10} is bound and essentially free
compound is found. With energized mitochondria, MitoQ10 is most likely bound at the matrix-facing surface of the inner membrane, with the triphenylphosphonium cation in a potential energy well close to the surface. The hydrophobic side chain is inserted into the membrane [96].

4.3. MitoQ10 analogs

Due to the necessity to treat mitochondrial dysfunction, numerous modifications of MitoQ10, based on the original design were subsequently reported. Instead of quinone, such derivatives bear vitamin E (Mito-αToc), dihydroethidium (MitoSOX™ Red [97]), nitroxide (Mito-Tempol, Mito-CP and Mito-CTP) [98,99], ebelen (a mimic of glutathione peroxidase), MnSalen [100], NO donor (MitoSNO [100]), and boronic acid peroxide sensor (MitoB [101]). MitoSOX™ Red, where redox-able moiety is dihydroethidium (a stoichiometric scavenger of O2•−), has been widely utilized as a mechanistic tool to prove the involvement of mitochondrially produced superoxide in oxidative stress [102]. Caution needs to be exercised as the effect of Mito moiety on cellular bioenergetics was reported [103].

4.4. Therapeutic effects of MitoQ10

The compound has thus far been employed in numerous studies and has already proven efficacious in animal models of oxidative stress, such as type I diabetes nephropathy, cold storage of renal cells and kidneys, cardiac ischemia/reperfusion, endotoxin-induced cardiac dysfunction, doxorubicin-induced cardiac toxicity, protection against increase in blood pressure in spontaneously hypertensive rats, and prevention of amyloid β-induced impairments in hippocampal synaptic plasticity in wild-type hippocampal slices treated with exogenous amyloid β peptide. It has been also tested in two phase-II clinical trials [104]. MitoQ10 was tested on its ability to slow down Parkinson’s disease progression, where no difference in the ability to slow down Parkinson’s disease progression, where no difference was seen between placebo and MitoQ10 groups. The study provides evidence in +2 oxidation state. Examples are Mn(II) complexes, MnBr8–NHE, the metal site becomes so electron-depleted that oxidation of a metal complex would become unfavorable; i.e. the oxidation of Mn porphyrin would become a rate-limiting step (Eq.(2)). Thus, further dismutation is electrostatically facilitated, as the superoxide anions are pulled toward the metal center through a tunnel encircled by positively charged amino acids[108]. We attempted to derivatize metalloporphyrins by mimicking the thermodynamics and electrostatics of the enzyme catalysis. The unsubstituted porphyrins have E1/2 for the Mn10/Mn11 redox couple ~~200 to ~300 mV vs NHE and cannot be reduced with O2•− in the step one of the dismutation process (Eq. (1)); the metal site reduction was a rate-limiting step (Fig. 5) [82,109]. In order to make the metal site more reducible, the electron-withdrawing groups were attached to the porphyrin ring in meso and beta positions which resulted in a significant increase in Mn electron-deficiency which translated into a significant increase in E1/2. Across the wide range of compounds thus far synthesized and commercially obtained, the E1/2 was increased by up to ~800 mV relative to unsubstituted Mn porphyrins; the MnCl5−NO2ONOO− has the highest E1/2 of +560 mV vs NHE [46]. Based on compounds explored, the structure-activity relationship (SAR) was essentially established [110], and later revised (Fig. 6). SAR shows that as the E1/2 increases, the kcat increases as well. At E1/2 ~+200 mV, both steps of the dismutation process occur with similar rate constants [109]. As E1/2 becomes more positive and increases beyond +400 mV vs NHE, the metal site becomes so electron-deficient that it gets stabilized in +2 oxidation state. Examples are Mn(II) complexes, MnBr8–NHE, TM-3(4)-PyP4+ and MnCl5TE-2-PyP4+ (Table 1) [44–46]. These compounds are not stable enough under physiological pH conditions and readily lose metal. They are, however, excellent mechanistic tools, proving that even a simple porphyrin ligand could be modified to achieve the catalytic potency of a protein structure. Further increase in E1/2 would stabilize Mn +2 oxidation state so much that the oxidation of a metal complex would become unfavorable; i.e. the oxidation of Mn porphyrin would become a rate-limiting step (Eq. (2)). Thus, such complexes would be poor SOD mimics also. Based on SAR, the ortho isomeric cationic Mn(III) N-alkylpyrrolyldoporphyrins were identified as the most efficacious SOD mimics thus far synthesized (Fig. 6). Fig. 6 further clearly shows that at E1/2 ~+200 mV the cationic Mn porphyrins are ≥100-fold more potent than compounds that have no charge or possess anionic charges on their periphery [44–46]. Such data point to the crucial impact of electrostatics on the catalysis of O2•− dismutation by MnPs. In summary, the exploration of the design of SOD mimics shows that ortho isomeric compounds possess a key property that is essential for their ability to catalyze O2•−

5. Mn porphyrins

5.1. Optimization of kcat(O2•−), bioavailability and toxicity

Mn porphyrins are among the most potent and true catalysts of O2•− dismutation, with kcat reaching the potency of SOD enzymes. They have been designed to mimic the action of the enzyme catalytic site. The detailed chemistry, biochemistry and biology of Mn porphyrins have been reviewed recently [44–46], and are briefly summarized below with most recent data included.

The reduction potential of the metal site of the enzyme, regardless of the type of metal (Cu, Mn, Fe or Ni), is around the midway (~300 mV vs NHE), between the potential for oxidation (~160 mV vs NHE) and the reduction of superoxide (~900 mV vs NHE) (Fig. 5). Therefore, both steps of the catalytic cycle are equally favored thermodynamically; consequently, both oxidation and reduction of O2•− by enzyme occur with the identical rate constant of ~2×107 M−1 s−1 [105–107]. Further, dismutation is electrostatically facilitated, as the superoxide anions are pulled toward the metal center through a tunnel encircled with positively charged amino acids [108]. We attempted to derivatize metalloporphyrins by mimicking the thermodynamics and electrostatics of the enzyme catalysis. The unsubstituted porphyrins have E1/2 for the Mn10/Mn11 redox couple ~200 to ~300 mV vs NHE and cannot be reduced with O2•− in the step one of the dismutation process (Eq. (1)); the metal site reduction was a rate-limiting step (Fig. 5) [82,109]. In order to make the metal site more reducible, the electron-withdrawing groups were attached to the porphyrin ring in meso and beta positions which resulted in a significant increase in Mn electron-deficiency which translated into a significant increase in E1/2. Across the wide range of compounds thus far synthesized and commercially obtained, the E1/2 was increased by up to ~800 mV relative to unsubstituted Mn porphyrins; the MnCl5−NO2ONOO− has the highest E1/2 of +560 mV vs NHE [46]. Based on compounds explored, the structure-activity relationship (SAR) was essentially established [110], and later revised (Fig. 6). SAR shows that as the E1/2 increases, the kcat increases as well. At E1/2 ~+200 mV, both steps of the dismutation process occur with similar rate constants [109]. As E1/2 becomes more positive and increases beyond +400 mV vs NHE, the metal site becomes so electron-deficient that it gets stabilized in +2 oxidation state. Examples are Mn(II) complexes, MnBr8–NHE, TM-3(4)-PyP4+ and MnCl5TE-2-PyP4+ (Table 1) [44–46]. These compounds are not stable enough under physiological pH conditions and readily lose metal. They are, however, excellent mechanistic tools, proving that even a simple porphyrin ligand could be modified to achieve the catalytic potency of a protein structure. Further increase in E1/2 would stabilize Mn +2 oxidation state so much that the oxidation of a metal complex would become unfavorable; i.e. the oxidation of Mn porphyrin would become a rate-limiting step (Eq. (2)). Thus, such complexes would be poor SOD mimics also. Based on SAR, the ortho isomeric cationic Mn(III) N-alkylpyrrolyldoporphyrins were identified as the most efficacious SOD mimics thus far synthesized (Fig. 6). Fig. 6 further clearly shows that at E1/2 ~+200 mV the cationic Mn porphyrins are ≥100-fold more potent than compounds that have no charge or possess anionic charges on their periphery [44–46]. Such data point to the crucial impact of electrostatics on the catalysis of O2•− dismutation by MnPs. In summary, the exploration of the design of SOD mimics shows that ortho isomeric compounds possess a key property that is essential for their ability to catalyze O2•−

Fig. 4. The mechanism of action of MitoQ with respect to scavenging O2•−. These redox reactions are similar to those of ubiquinone in mitochondrial electron transport chain, and are responsible for the production of low levels of superoxide. The rate constants listed refer to water. αTocH and αToc refer to α-tocopherol and α-tocopherol radical, respectively.

\[ \text{MitoQH} \overset{k_f}{\rightarrow} \text{MitoQ} + \text{O}_2 \]

\[ \text{Dismutation} \]

\[ \text{MitoQH}_2 \overset{k_f}{\rightarrow} \text{MitoQH} + \text{O}_2 \]

\[ \text{R} = \text{(CH}_2\text{)}_{10}\text{P}^+(\text{C}_6\text{H}_5)_3, \text{MitoQ}=\text{MitoQ}_{10} \]
dismutation: electron-withdrawing cationic pyridyl nitrogens close to the Mn site which (1) make the Mn(III) site electron-deficient and thus eager to accept electrons from the superoxide in the first step of the dismutation process; and (2) attract anionic superoxide toward the singly charged Mn site.

The timeline for the optimization of SOD mimics is depicted in Fig. 7. In Phase I we aimed at designing compounds whose $k_{cat}(O_2^-)$ approaches that of an enzyme. As our research progressed, it became clear that the efficacy in vivo would also depend on the lipophilicity of the compound, as well as on its bulkiness, size, and shape (Fig. 7). The latter properties may hinder the cationic charges and thus suppress the unfavorable approach of the compound to the targeted biological molecules and thus decrease MnP toxicity. For example, the interaction of cationic charges of the more planar para isomer, MnTM-4-PyP5+ with nucleic acids, precludes the approach of $O_2^-$ to the Mn site, and in turn leads to the complete loss of its SOD-like activity in vivo. Further, with cationic MnPs, a blood pressure drop, as a side effect, was found in animal studies [44–46]. The effect is lower with MnTnHex-2-PyP5+ than with MnTE-2-PyP5+.

presumably due to the larger hindrance of cationic charges by longer alkyl chains [112,113]. Yet, in certain cases the hindrance of charges may be unfavorable. For example, the cationic charges may favor the approach of Mn porphyrin to the deprotonated anionic cysteine residues of signaling proteins such as p50 and p65 subunits of NF-κB, and thus facilitate the cysteine oxidation or glutathionylation, respectively, which in turn would prevent NF-κB DNA binding and suppress excessive inflammation [27,114,115]. The first potent porphyrin-based SOD mimics, MnTM-2-PyP5+ and MnTE-2-PyP5+ (Fig. 1), were developed 15 years ago. Based on the same principles, di-ortho imidazolium analog, MnTDE-2-ImP5+, was subsequently synthesized. Because these compounds are fairly hydrophilic and bear total pentacationic charge, it seemed at first unlikely that they would cross the blood brain barrier (BBB) and target mitochondria. In an effort to facilitate transport across the BBB and enhance accumulation within mitochondria, we have optimized the properties of the cationic porphyrin by lengthening the alkyl chains of meso pyridyl groups. While maintaining the total cationic charge, and therefore the redox activity, we synthesized lipophilic Mn
porphyrins with longer hydrophobic alkyl chains: MnTnHex-2-PyP$_{5}^{5+}$ and MnTnOct-2-PyP$_{5}^{5+}$. We subsequently showed that: (1) a number of carbon atoms in alkyl chains are proportional to MnP lipophilicity (the increase in alkyl chain length for one carbon atom increases MnP lipophilicity ~10-fold) (Table 1) [91]; and (2) lipophilic members accumulate more in $E. coli$ and exert their efficacy at significantly lower doses than hydrophilic analogs do [91,116]. MnTnHex-2-PyP$_{5}^{5+}$ and MnTnOct-2-PyP$_{5}^{5+}$ are ~10,000- and 300,000-fold more lipophilic than MnTE-2-PyP$_{5}^{5+}$ [44–46]. Such a remarkable gain in lipophilicity translates into a more than 3-orders of magnitude increased in vivo efficacy of lipophilic Mn porphyrins. Their therapeutic superiority is detailed below under “The in vitro and in vivo efficacy of Mn porphyrins.”

We have originally limited ourselves to the study of ortho isomeric Mn(III) $N$-alkylpyridylporphyrins as they have the highest $k_{cat}(O_2^-)$ among MnPs studied. Yet, our growing insight into the magnitude of the effect of lipophilicity upon in vivo efficacy tempted us to revisit the 10-fold more lipophilic meta isomers. A nice set of data obtained in an $E. coli$ study shows that higher bioavailability of a MnP can markedly compensate for its inferior redox potency. The meta isomer MnTE-3-PyP$_{5}^{5+}$ has a 10-fold lower SOD potency, but is 10-fold more lipophilic than ortho MnTE-2-PyP$_{5}^{5+}$. In turn, MnTE-3-PyP$_{5}^{5+}$ accumulates at 10-fold higher levels within $E. coli$ cell than MnTE-2-PyP$_{5}^{5+}$. Consequently, both compounds are equally able to protect SOD-deficient $E. coli$ strain when growing aerobically [91].

The toxicity of cationic Mn(III) alkylpyridylporphyrins is at least in part due to their micellar character, which arises from their polar cationic nitrogens and hydrophobic alkyl chains (Fig. 7). Our most recent efforts have been directed toward reducing the toxicity of the lipophilic longer alkyl-chain analogs. Two strategies were applied. Firstly, oxygen was introduced at the end of each alkyl chain [109,117]; however this strategy significantly reduced MnP lipophilicity. The second approach was to bury oxygen atoms deep into each of the alkyl chains, thus closer to the pyridyl nitrogens [118]; such strategy preserved the lipophilicity and the SOD-like potency of MnP, while largely diminished its toxicity.
6. Accumulation of Mn porphyrins in mitochondria

The excessive pentacationic charge of MnTE-2-PyP$^{5+}$ sets initial doubts on its ability to enter mitochondria and cross the BBB. However, it was shown by Liberaman's, Skulachev's and Murphy's groups that cationic charge has a critical role in driving drug mitochondrial localization [51]. The St. Clair’s group recently showed that cationic MnTE-2-PyP$^{5+}$ reduces incidence and multiplicity of papillomas in a mouse skin carcinogenesis model in a manner similar to MnSOD enzyme (see details under Skin carcinogenesis section) [119]. The data therefore suggest that the MnPs end up in mitochondria and more specifically in the mitochondrial matrix. Concurrently, Ferrer-Sueta et al. showed that $\geq 3 \mu M$ MnTE-2-PyP$^{5+}$ protects sub mitochondrion particles against oxidative stress imposed by peroxynitrite [120]. Subsequently, we quantified the accumulation of MnTE-2-PyP$^{5+}$ in mouse heart mitochondria: at 5.4 $\mu M$, its levels are high enough to protect mitochondria against oxidative damage [121].

6.1. Mouse heart studies

To test the hypothesis that lipophilicity has a critical impact on the mitochondrial targeting of Mn porphyrins, we performed a mouse study on MnTnHex-2-PyP$^{5+}$. The data are discussed in relation to the mitochondrial accumulation of ~10,000-fold less lipophilic MnTE-2-PyP$^{5+}$ (Fig. 2, Table 1) [121]. MnHex-2-PyP$^{5+}$ was given ip at a maximal tolerable single dose of 2 mg/kg, while MnTE-2-PyP$^{5+}$ was given ip at 10 mg/kg. The in vivo levels of MnPs were determined as previously described, employing the LC/ESI-MS/MS method [45,122]. MnTE-2-PyP$^{5+}$ was found in mouse heart mitochondria at (2.95±1.24) ng/mg protein [121], and MnTnHex-2-PyP$^{5+}$ was found at (12.17±8.48) ng/mg protein. Given the average value of mitochondrial volume of 0.6 $\mu L/mg$ protein [123–130], the concentration of MnTE-2-PyP$^{5+}$ in mitochondria was 5.1 $\mu M$ while it was 21.0 $\mu M$ in the case of MnTnHex-2-PyP$^{5+}$. Assuming a linearity in a drug accumulation upon dose increase, the data are normalized to a mg of drug injected and show that MnTnHex-2-PyP$^{5+}$ accumulates ~20-fold more in mitochondria than does MnTE-2-PyP$^{5+}$ (Fig. 8B). When cytosolic and mitochondrial fractions are compared, MnTnHex-2-PyP$^{5+}$ [121] accumulates ~5-fold more in mitochondria than in cytosol (Fig. 8). The study supports the key impact of lipophilicity on the transport of MnPs into cells and its accumulation in mitochondria.

6.2. S. cerevisiae studies

The mouse cardiac data parallel the data generated with S. cerevisiae. The accumulation of MnPs within mitochondria is proportional to the compound lipophilicity, which in turn is proportional to the length of phorphyrin alkyl chains [122,131]. The compound bearing methyl (M) chains, MnTM-2-PyP$^{5+}$ distributes evenly between yeast mitochondria and cytosol, MnTE-2-PyP$^{5+}$ resides ~23-fold more in mitochondria than in cytosol, while the MnTnHex-2-PyP$^{5+}$ is $\geq 90\%$ in mitochondria [122,131].

6.3. E. coli studies

One of the hypotheses is that eukaryotic cell mitochondria are evolutionarily derived from bacteria [83]. Thus the E. coli membranes/wall (envelope) and cytosol may be viewed as analogous to the mouse mitochondrial membranes and matrix, respectively. Not surprisingly, therefore, the mouse mitochondrial data are in excellent agreement with the accumulation of cationic Mn porphyrins in E. coli [91] (Fig. 8C). The accumulation was followed in both SOD-deficient and wild strains of E. coli. The accumulation was higher in the SOD-deficient strain, where MnPs exerted a remarkable ability to substitute for the lack of cytosolic MnSOD and FeSOD [45,91]. In agreement with the mouse heart studies, the lipophilic member of the porphyrin series, MnTnHex-2-PyP$^{5+}$, resides at ~30-fold more in envelope and 100-fold more in the cytosol of E. coli than MnTE-2-PyP$^{5+}$ (Fig. 8C). E. coli data further show that all MnPs tend to distribute more in envelope than in the cytosol (Fig. 8C). While MnTnHex-2-PyP$^{5+}$ accumulates ~twice more in envelope than in cytosol, MnTE-2-PyP$^{5+}$ distributes ~10-fold more in envelope than in cytosol. The E. coli data also suggest that in addition to the mitochondrial matrix, MnTnHex-2-PyP$^{5+}$ could reside within mouse cardiac mitochondrial membranes, and/or be placed at the inner membrane/matrix interface, where the lipophilic chains may be stuck within the membrane while cationic heads reach the matrix (similar to MitoQ10). It can thus mimic both isoforms of mitochondrial enzymes: MnSOD and Cu/ZnSOD. Further studies are needed to address the compartmentalization of MnTnHex-2-PyP$^{5+}$ within mitochondria.

7. Accumulation of Mn porphyrins in brain

The critical effect of lipophilicity of MnPs upon their in vivo action is further evidenced in those animal studies where transport across BBB is required for their efficacy (stroke, subarachnoid hemorrhage, pain, cerebral palsy, neurologic disorders, etc) [42–44]. The hydrophilic MnTE-2-PyP$^{5+}$ accumulates in brain over a 7-day period after a single 10 mg/kg ip injection [121]. As expected, MnTnHex-2-PyP$^{5+}$ accumulates in brain at ~9-fold higher levels [112], which agrees with its 20-fold higher mitochondrial accumulation (Figs. 8 and 9). MnTE-2-PyP$^{5+}$ accumulates ~5-fold more in mitochondria than in cytosol, while the MnTnHex-2-PyP$^{5+}$ is $\geq 90\%$ in mitochondria [122,131].

Fig. 8. (A) Accumulation of MnTnHex-2-PyP$^{5+}$ in C57BL/6 mouse heart cytosol and mitochondria at 6 h after single ip injection of 2 mg/kg. Data obtained using the LC/ESI-MS/MS method [121]. (B) Comparison of the accumulation of hydrophilic MnTE-2-PyP$^{5+}$ and lipophilic MnTnHex-2-PyP$^{5+}$ in C57BL/6 mouse heart mitochondria at 6 h after single ip injection. (C) The accumulation of MnTE-2-PyP$^{5+}$ and MnTnHex-2-PyP$^{5+}$ in wild type AB1157 E. coli membranes/cell wall (envelope) and cytosol after E. coli was incubated for 1 h in the presence of 5 $\mu M$ Mn porphyrins in M9CA medium [91]. One of the present evolutionary hypotheses is that eukaryotic mitochondrial membranes and matrix are derived from E. coli envelope and cytosol, respectively [83]. Thus, the biodistribution within E. coli resembles the biodistribution within heart mitochondria. It must be noted that recalculation of the raw data, obtained with 10 mg/kg single ip injection of MnTE-2-PyP$^{5+}$ and 2 mg/kg single ip injection of MnTnHex-2-PyP$^{5+}$, were done assuming a linearity in drug accumulation in tissues and subcellular fragments upon dose increase.
2-PyP5+ and MnTnHex-2-PyP5+ were injected ip at 10 mg/kg and 2 mg/kg, respectively. Their mitochondrial and brain levels were recalculated per mg of drug injected, assuming a linearity in drug accumulation upon dose increase. Such agreement is due to the fact that in both cases the ability of MnP to cross lipid membranes plays a major role.

8. Accumulation of Mn porphyrins in tumor tissue

The first set of data on MnP accumulation in tumors was obtained in a 4T1 mouse breast cancer model where MnTnHex-2-PyP5+ was administered during the duration of experiment twice daily ip at 1.6 mg/kg with and without sodium ascorbate[132]. The Mn porphyrin accumulated ~5-fold more in tumor (sc xenografts were established on right flank) than in the muscle taken from the left leg[132]. The enhanced accumulation in tumor relative to muscle was observed when mice were treated either with MnP alone or with MnP/ascorbate. Combined administration with ascorbate is relevant due to the high levels of ascorbate in vivo, where MnP action is likely coupled to ascorbate redox cycling. Other reductants, such as glutathione, tetrahydrobiopterin and protein cysteine residues, may be also involved in MnP reduction (from MnII to MnIII) and its redox-cycling[44,114,115,133]. Once reduced, MnP loses a single charge from the Mn site and in turn becomes more hydrophobic[132]. The gain in lipophilicity is related to the length of porphyrin alkyl chains in a bell-shape fashion: ≥10-fold increase was found with MnTE-2-PyP5+ and MnTnHex-2-PyP5+[132]. Such increased lipophilicity may enhance MnP subcellular accumulation. Most recent data on MRI imaging of prostate cancer, employing Mn porphyrins as contrast agents, show also that MnTE-2-PyP5+ distributes more in prostate tumor than in the surrounding tissue[134].

9. Mechanism of action of Mn porphyrins

Alike MnSOD enzyme, the Mn porphyrins affect levels of reactive species and activation of transcription factors, whereby acting as fine cellular redox modulators. These actions may be independent or related, as reactive species are both strong oxidants and also major signaling species. The MnP-based SOD mimics have been proven efficacious in numerous in vitro and in vivo models, and the efficacy was reproduced in various laboratories both within and outside the United States[13,27,44–46,132].

9.1. Reactivity toward reactive species

Increased knowledge about the chemistry and biology of redox-active compounds and the role of reactive species and endogenous antioxidants makes it clear that synthetic SOD mimics as well as stoichiometric scavengers of superoxide are not specific towards O2− (Fig. 10). The possible reactions of Mn(III) substituted pyridyl(or imidazolyl)porphyrins toward several oxygen and nitrogen species, such as O2−, ONOO−, ClO−, NO2, CO3−, would produce antioxidative effects[44–46]. Under physiological conditions, H2O2 formed during dismutation is removed by abundant peroxide-removing systems. The ONOO− reacts with MnTE-2-PyP5+ which has Mn in +3 (kred=3.4×10 7 M−1 s−1 at 37 °C), and with MnTE-2-PyP6+ that contains Mn in +2 oxidation states (k≫107 M−1 s−1 at 37 °C)[135,136]. MnTE-2-PyP5+ reacts also with NO (k~106 M−1 s−1) [137]. Based on the preliminary data, MnTE-2-PyP5+ reacts rapidly with ClO− with a rate constant of k≫106 M−1 s−1 [Ferrer-Sueta et al., unpublished]. Based on the thermodynamic and kinetic data thus far published on ortho isomers, those MnPs that are potent SOD mimics would likely favor reaction with NO2 too.

Fig. 9. The distribution of MnTE-2-PyP5+ and MnTnHex-2-PyP5+ in murine brain at 24 h after single ip injection[112]. Brain levels of lipophilic MnTnHex-2-PyP5+ are 9-fold higher than of hydrophilic MnTE-2-PyP5+. MnTE-2-PyP5+ and MnTnHex-2-PyP5+ were injected ip at 10 mg/kg and 2 mg/kg, respectively. Data are expressed per mg of drug injected assuming a linearity in drug brain accumulation upon dose increase.

Fig. 10. The reactivity of Mn porphyrins toward reactive species (A) and transcription factors (B). The reactivity of Mn(III) substituted pyridyl(or imidazolyl)porphyrins toward several oxygen and nitrogen species, such as O2−, ONOO−, ClO−, NO2, CO3−, would produce antioxidative effects[44–46]. Under physiological conditions, H2O2 formed during dismutation is removed by abundant peroxide-removing systems. The ONOO− reacts with MnTE-2-PyP5+ which has Mn in +3 (kred=3.4×10 7 M−1 s−1 at 37 °C), and with MnTE-2-PyP6+ that contains Mn in +2 oxidation states (k≫107 M−1 s−1 at 37 °C)[135,136]. MnTE-2-PyP5+ reacts also with NO (k~106 M−1 s−1) [137]. Based on the preliminary data, MnTE-2-PyP5+ reacts rapidly with ClO− with a rate constant of k≫106 M−1 s−1 [Ferrer-Sueta et al., unpublished]. Based on the thermodynamic and kinetic data thus far published on ortho isomers, those MnPs that are potent SOD mimics would likely favor reaction with NO2 too.
challenging, requiring multiple controls and genetic tools to single out the predominant species involved.

While mechanistic aspects need further exploration, the beneficial therapeutic effects are obvious because the failure to remove O$_2^-$ by MnP would result in increased levels of its progeny, such as, OH, ONOO$^-$, NO$_2^-$, CO$_3^-$, and lipid peroxyl radicals. Thus, the potent MnP-based SOD mimics would efficiently suppress not only the levels of O$_2^-$ but of all species originated from it.

The electron-deficient metal porphyrin center favors binding of the anionic ONOO$^-$ to Mn(III) or Mn(II) (reduced by cellular reductant or O$_2^-$), which is followed by the one-electron or two-electron reductions of ONOO$^-$ to NO$_2^-$ or NO$_2^-$, respectively [135,136]. Reduction of CO$_3^-$ by MnPs and reactivity toward NO have also been reported (Fig. 10A). Further, preliminary data [Ferrer-Sueta et al., unpublished] indicate that MnPs have high activity to reduce ClO$_2^-$. Reduced Mn(II) porphyrins have fairly high reactivity towards molecular oxygen as well (Fig. 11). Among the rate constants thus far determined, the highest are those related to the elimination of O$_2^-$ and CO$_2^-$, followed by $k_{red}(ONOO^-)$ [44-46,136]. The type of reaction favored in vivo will ultimately depend upon the levels of MnPs, reactive species, cellular reductants and their co-localization with MnPs.

9.2. Mn porphyrins and cellular reductants

Electron deficiency of a Mn site facilitates easy reduction of Mn porphyrins not only with O$_2^-$ but with cellular reductants, such as ascorbate, glutathione, tetrahydrobiopterin and flavoproteins of mitochondrial respiration. As those reductants are highly abundant in vivo, the removal of O$_2^-$ by MnPs would likely be coupled with redox cycling of ascorbate or glutathione [133,138,139]. Thus, in a first step, ascorbate would reduce Mn$^{III}P$ to Mn$^{II}P$. Subsequently, the Mn$^{II}P$ would reduct O$_2$ to H$_2$O$_2$. Consequently, MnPs may in vivo act as superoxide reductases rather than superoxide dismutases [140].

MnP could in vivo increase levels of H$_2$O$_2$. While mechanistic aspects need further exploration, the beneficial therapeutic effects are obvious because the failure to remove O$_2^-$ by MnP would result in increased levels of its progeny, such as, OH, ONOO$^-$, NO$_2^-$, CO$_3^-$, and lipid peroxyl radicals. Thus, the potent MnP-based SOD mimics would efficiently suppress not only the levels of O$_2^-$ but of all species originated from it.

While mechanistic aspects need further exploration, the beneficial therapeutic effects are obvious because the failure to remove O$_2^-$ by MnP would result in increased levels of its progeny, such as, OH, ONOO$^-$, NO$_2^-$, CO$_3^-$, and lipid peroxyl radicals. Thus, the potent MnP-based SOD mimics would efficiently suppress not only the levels of O$_2^-$ but of all species originated from it.

The electron-deficient metal porphyrin center favors binding of the anionic ONOO$^-$ to Mn(III) or Mn(II) (reduced by cellular reductant or O$_2^-$), which is followed by the one-electron or two-electron reductions of ONOO$^-$ to NO$_2^-$ or NO$_2^-$, respectively [135,136]. Reduction of CO$_3^-$ by MnPs and reactivity toward NO have also been reported (Fig. 10A). Further, preliminary data [Ferrer-Sueta et al., unpublished] indicate that MnPs have high activity to reduce ClO$_2^-$. Reduced Mn(II) porphyrins have fairly high reactivity towards molecular oxygen as well (Fig. 11). Among the rate constants thus far determined, the highest are those related to the elimination of O$_2^-$ and CO$_2^-$, followed by $k_{red}(ONOO^-)$ [44-46,136]. The type of reaction favored in vivo will ultimately depend upon the levels of MnPs, reactive species, cellular reductants and their co-localization with MnPs.

9.2. Mn porphyrins and cellular reductants

Electron deficiency of a Mn site facilitates easy reduction of Mn porphyrins not only with O$_2^-$ but with cellular reductants, such as ascorbate, glutathione, tetrahydrobiopterin and flavoproteins of mitochondrial respiration. As those reductants are highly abundant in vivo, the removal of O$_2^-$ by MnPs would likely be coupled with redox cycling of ascorbate or glutathione [133,138,139]. Thus, in a first step, ascorbate would reduce Mn$^{III}P$ to Mn$^{II}P$. Subsequently, the Mn$^{II}P$ would reduct O$_2$ to H$_2$O$_2$. Consequently, MnPs may in vivo act as superoxide reductases rather than superoxide dismutases [140].

MnP could in vivo increase levels of H$_2$O$_2$. While mechanistic aspects need further exploration, the beneficial therapeutic effects are obvious because the failure to remove O$_2^-$ by MnP would result in increased levels of its progeny, such as, OH, ONOO$^-$, NO$_2^-$, CO$_3^-$, and lipid peroxyl radicals. Thus, the potent MnP-based SOD mimics would efficiently suppress not only the levels of O$_2^-$ but of all species originated from it.

Electron deficiency of a Mn site facilitates easy reduction of Mn porphyrins not only with O$_2^-$ but with cellular reductants, such as ascorbate, glutathione, tetrahydrobiopterin and flavoproteins of mitochondrial respiration. As those reductants are highly abundant in vivo, the removal of O$_2^-$ by MnPs would likely be coupled with redox cycling of ascorbate or glutathione [133,138,139]. Thus, in a first step, ascorbate would reduce Mn$^{III}P$ to Mn$^{II}P$. Subsequently, the Mn$^{II}P$ would reduct O$_2$ to H$_2$O$_2$. Consequently, MnPs may in vivo act as superoxide reductases rather than superoxide dismutases [140].

MnP could in vivo increase levels of H$_2$O$_2$. While mechanistic aspects need further exploration, the beneficial therapeutic effects are obvious because the failure to remove O$_2^-$ by MnP would result in increased levels of its progeny, such as, OH, ONOO$^-$, NO$_2^-$, CO$_3^-$, and lipid peroxyl radicals. Thus, the potent MnP-based SOD mimics would efficiently suppress not only the levels of O$_2^-$ but of all species originated from it.
9.4. Timing of MnP administration

MnTM-2-PyP⁵⁺ ameliorates diabetes-induced oxidative stress and affects life-span of diabetic rats when administered for 2 months subcutaneously at 1 mg/kg five times/week followed by a week of rest, starting at the onset of diabetes [160]. MnTM-2-PyP⁵⁺ treatment suppressed lipid peroxidation and nitrotyrosine formation, prevented aconitase inactivation, and reversed the induction of Na⁺/H⁺ exchangers [147]. However, when the administration started 1 week after the onset of diabetes, no protection against oxidative stress and diabetic complications was detected [161]. Moreover, MnTM-2-PyP⁵⁺ contributed to the kidney damage: increased urinary protein, lysosome and blood urea nitrogen levels were found. Further, its administration increased malondialdehyde levels and decreased activity of glucose-6-phosphate dehydrogenase. This enzyme has a unique role, as it is a principal source of cellular reducing equivalents in the form of NADPH, which supports glutathione regeneration. In stroke studies, MnTE-2-PyP⁵⁺ was only efficacious if given not later than 6 h after middle cerebral artery occlusion (MCAO) [162]. Differences in the effects produced with different dosing regimens are likely related to the changes in the cellular balance between the reactive species and endogenous antioxidant as the disease progresses. Tan et al. recently showed a remarkable ability of MnThHex-2-PyP⁵⁺ to reduce the severity of motor deficit in a cerebral palsy model, but only when given to rabbit dam prior to uterine ischemia/reperfusion. The effect was lost if MnP was given during reperfusion, which is due to its slow accumulation in fetal brain (see below under Cerebral palsy section) [163].

9.5. Mn porphyrins and tumors

Numerous reports provide evidence that tumors are more oxidatively stressed than normal tissue [164–177]; moreover, tumors adapt so that they utilize oxidative stress as a “signaling” tool for their own progression. Yet, tumors are also vulnerable to any additional increase in oxidative stress, which may eventually lead to cell apoptosis, exemplified by a narrower bell-shape curve in Fig. 12. Data have been provided which show that MnP can suppress tumor progression by either: (1) removal of reactive species as witnessed by the suppression of oxidative stress (see below); or (2) increased production of reactive species (Fig. 12). The type of MnP action depends on cellular redox status, timing of MnP administration, levels of reactive species and MnPs and their co-localization, levels of endogenous antioxidants, and MnP cellular and subcellular distribution.

4T1 breast cancer cellular and mouse studies provide evidence that removal of reactive species by MnTE-2-PyP⁵⁺ prevents HIF-1α activation and VEGF expression, and thus tumor angiogenesis. Concomitant decrease in oxidative stress was detected [143,148,149]. Similarly, in a skin carcinogenesis mouse model, MnP suppressed AP-1 activation and protein oxidative modification [178]. When different cancer cell lines were cultured in the presence of MnP and an excess of ascorbate, the effects observed were pro-oxidative; a similar trend was seen in a 4T1 mouse model [142]. These effects are likely due to the inability of endogenous enzymes to manage excessive H₂O₂ produced by MnP-catalyzed ascorbate oxidation (Fig. 11) [142].

Anticancer drugs which function by increasing tumor oxidative burden have been widely used. Prostate cancer cells often exert increased generation of reactive oxygen species from mitochondria [179] or NADPH oxidases [180], which is in part due to the decreased levels of antioxidant enzymes, such as MnSOD, Cu,ZnSOD, and catalase [181,182]. Parthenolide selectively activates NADPH oxidases, mediating oxidative stress in prostate cancer cells by both increasing ROS generation and decreasing antioxidant defense capacity, which results in radiosensitizing effects. Yet, the oxidative stress in normal prostate epithelial cells was reduced [183].

9.6. The in vivo and in vitro efficacy data

Below are summarized data that show more than 1000-fold increase in the in vivo efficacy of lipophilic relative to hydrophilic MnPs, which at least in part reflects their ability to enter the cell and its critical compartments and cross the BBB. Also, a few studies are cited whose data strongly suggest that MnPs can indeed mimic mitochondrial MnSOD.

MnThHex-2-PyP⁵⁺ has been studied in several models of central nervous system injuries and has been found efficacious at very low single or multiple doses ranging from 0.05 to 3.2 mg/kg/day in animal models and from 0.1 to 1 μM in E. coli studies. The hydrophilic MnTE-2-PyP⁵⁺ was up to 120-fold less efficacious at 6 to 15 mg/kg or multiple doses (ip, iv, sc, ivc) in animal models, and from ~20 to 50 μM in cellular models [44,46]. MnThHex-2-PyP⁵⁺ was remarkably efficacious in stroke and hemorrhage rodent models [112,150], rabbit cerebral palsy [163,191], brain glioma study [192], organotypic hypopapillary slice model of oxygen glucose deprivation [190], rat eye hypertension [193], rat lung radiation [194], rat renal ischemia reperfusion model [144,195], E. coli model [116], and ataxia telangiectasia radiation cellular model [196]. The most remarkable efficacy of MnThHex-2-PyP⁵⁺ was found in the rabbit cerebral palsy model (see below under Cerebral palsy section). Ataxia telangiectasia (AT) is a rare neurodegenerative disease in which the impaired mitochondrial function of lymphoblastoids causes AT patients to be particularly sensitive to radiation. In a cellular model, the 1 μM MnThHex-2-PyP⁵⁺ was the most efficacious among a wide range of compounds studied, followed by 56 μM MnTM₅₋₂-PyP⁵⁺. MnThHex-2-PyP⁵⁺ describes a preparation that was incompletely quaternized (methylated) MnTh₂-PyP⁵⁺. It contains Mn porphyrins bearing different number of methyl groups from 0 to 4, and therefore total charge from 1+ to 5+. The preparation was thus more lipophilic relative to a single compound, MnTM₂-PyP⁵⁺, bearing 4 methyl groups and a pentacationic charge. MnCl₂ was marginally protective, but it was used at only 1 μM concentration. Other compounds studied are: MnSalen derivatives (EUK-8, EUK-134 and EUK-189), Mn cyclic polyamines (M40403, M40304), MnTE₂-PyP³⁺, PEGylated porphyrin, MnTETG-2-PyP⁵⁺, and MnBr₂ TSP⁺⁻ [196]. The study suggests that positive charge of a compound and its lipophilicity are key features that allow MnThHex-2-PyP⁵⁺ to radioprotect mitochondria. In an organotypic hypopapillary slice model of oxygen/glucose deprivation [190], we explored the most lipophilic member of the alkylpyridyl series: the octyl compound, MnOct-2-PyP⁵⁺. The compound was >1000-fold more efficacious than

![Fig. 12. A tumor is frequently under oxidative stress, a "physiological" status that is visualized here by the maximum of its bell shape curve shifted for ΔS towards higher RS levels. The increased level of RS is a signal for the upregulation of the genes needed to support tumor angiogenesis and progression [184,185]. However, a tumor is vulnerable to any additional increase in oxidative stress, which may eventually lead to cell apoptosis, exemplified by a narrower bell-shape curve in Fig. 12. Data have been provided which show that MnP can suppress tumor progression by either: (1) removal of reactive species as witnessed by the suppression of oxidative stress (see below); or (2) increased production of reactive species (Fig. 12). The type of MnP action depends on cellular redox status, timing of MnP administration, levels of reactive species and MnPs and their co-localization, levels of endogenous antioxidants, and MnP cellular and subcellular distribution.](image-url)
hydrophilic MnTE-2-PyP5+ and its diethylimidazolium analog, MnTDE-2-ImP5+. In a brain tumor study, MnTnHex-2-PyP5+ was an efficacious radio- and chemo-sensitizer. Its efficacy is at least in part due to its ability to cross BBB and accumulate in brain mitochondria [44].

However, lipophilic MnTnHex-2-PyP5+ also has micellar characteristics, as it bears cationic polar heads and hydrophobic chains. This contributes at least in part to its increased toxicity. Zn analog, ZnTnHex-2-PyP5+, exerts no dark toxicity [197], which suggests that redox activity of a metal site contributes to the toxicity of MnTnHex-2-PyP5+. Our efforts were recently directed towards reducing toxicity while maintaining high redox potency and high lipophilicity of MnTnHex-2-PyP5+. Its oxygen derivative, MnTnBuOE-2-PyP5+, was synthesized (Fig. 7), and has enhanced kcat(O2−), lipophilicity and greatly reduced toxicity (Fig. 7) [118].

9.7. Skin carcinogenesis

In a TPA-skin carcinogenesis model, MnTE-2-PyP5+ was administered in a timely manner, after cells underwent apoptosis and before proliferation, and was applied to a mouse skin at 5 ng/day, 5 days per week, for 14 weeks [178]. Mn porphyrin decreased the incidence and multiplicity of papillomas from 31 (in control mice) to 5 (Fig. 13). In a similar study with MnSOD-overexpressor mice, MnSOD suppressed both apoptosis and proliferation, and the final outcome was therefore diminished: the number of papillomas decreased from 19 to 9 (Fig. 13) [20, 178]. Furthermore, MnTE-2-PyP5+ suppressed oxidative stress as shown by the reduced levels of carbonylated proteins. It greatly suppressed AP-1 activation and proliferation and consequently the incidence of cancer, without affecting levels of the pro-apoptotic, tumor suppressor transcription factor p53 (Fig. 13). The MnP antioxidative mode of action was proposed as a means to remove signaling reactive species, and thereby spare biological targets and prevent transcriptional activity.

9.8. UVB-mediated skin damage

Mitochondrial DNA, mtDNA, is organized as nucleoids in the mitochondrial inner membrane. Nucleoids consist of mtDNA-protein macromolecular complexes containing 2–8 mtDNA molecules associated with various proteins such as mitochondrial transcription factor A, mitochondrial single-strand DNA binding protein and mitochondrial DNA polymerase Poly protein [198]. Poly is the only known polymerase enzyme responsible for the replication and repair of mtDNA. mtDNA is more sensitive to UV-induced damage than is nuclear DNA, as it lacks histones and an elaborate repair system. Depilated mice in resting phase of hair cycle were irradiated with 5 kJ/m2 of UVB radiation. The oxidative damage of Poly protein (its nitration and subsequent inactivation [198–200]) was greatly reduced in MnSOD+/+ wild type mice as compared to MnSOD knockout mice (Fig. 14A). The UVB radiation did not affect levels of Poly. Such data indicate that MnSOD is a mitochondrial fidelity protein that protects Poly against UV-induced inactivation. The full protection of Poly was observed (either at 1 h or 24 h after UVB treatment) in skin lysates of MnSOD+/+ mice, treated twice daily ip for 2 days before UVB with 5 mg/kg of MnTE-2-PyP5+ (Fig. 14) [198]. The data provide further evidence that this MnP is indeed a MnSOD mimic.

9.9. Pain study — chronic morphine tolerance

Acute morphine has been shown to suppress pain in a mouse paw exposed to heat. When given chronically over 4 days, the analgesic
The effect was lost but was fully restored if morphine was co-administered with Mn porphyrins (Fig. 15) [44,201]. Chronic morphine tolerance causes MnSOD inactivation but does not affect its expression levels (Fig. 15). The oxidative modifications of neurotransmitters, such as glutamate transferase and glutamine synthase, also contribute to the development of chronic morphine tolerance [201,202]. Both MnTE-2-PyP5+ and MnTnHex-2-PyP5+ were able to prevent MnSOD inactivation (Fig. 15) [201]. The activity of Cu,ZnSOD was affected by neither chronic morphine tolerance nor by MnPs (Fig. 15). A lipophilic MnTnHex-2-PyP5+ was ~30-fold more efficacious, which agrees well with its ability to accumulate ~20-fold more in mitochondria than does MnTE-2-PyP5+. As inhibition of chronic morphine tolerance occurs at the level of the central nervous system, the ability of a drug to cross the BBB also plays a role. MnTnHex-2-PyP5+ is able to cross the BBB ~9-fold more than MnTE-2-PyP5+ [112,122]. Oxidative stress was suppressed, as seen by the reduction in formation of 8-hydroxy-2′-deoxyguanosine [122].

9.10. Renal ischemia–reperfusion

Two sets of data on renal/ischemia have been reported. The first study by Saba et al. provided data on MnSOD inactivation which is similar to the data obtained in a mouse pain model (Fig. 16) [195]. Rats were subjected to a right nephrectomy and renal artery occlusion (40 min) followed by 18 h reperfusion. MnP was given as a single 0.05 mg/kg injection via iv route at 30 min and 24 h before ischemia/reperfusion. The levels of MnSOD were not affected by ischemia/reperfusion, yet MnTnHex-2-PyP5+ prevented enzyme inactivation if given 24 h before the oxidative insult. Further, Mn porphyrin significantly suppressed the protein nitrotyrosine formation in a renal tissue. ATP synthase-β subunit was identified as a key protein induced by MnP and a complex V (ATP synthase) as a target of renal ischemia/reperfusion.

The second study of rat warm renal ischemia by Dorai et al. was conducted with 0.1 mg/kg MnTnHex-2-PyP5+. The MnP was given intramuscularly at 24 h before, during renal artery clamp and 24 h after surgery, as a part of a cocktail containing Krebs cycle intermediates, α-ketoglutarate and L-aspartate, and growth factors bFGF, BMP-7, SDF-1 and EPO [144]. At 48 h, the kidneys were harvested and examined. Significant reversal of morphological changes and a decrease in the specific ischemic markers lipocalin-2, mucin-1 and galectin-3 were detected. Quantitative reverse transcriptase–polymerase chain reaction in treated animals reveal multifold upregulation of several antioxidant genes, including MnSOD, extracellular Cu,ZnSPOD, peroxiredoxins and thioredoxin reductase.

9.11. Cerebral palsy

The role of MnSOD and mitochondria in neurological disorders, such as cerebral palsy and epilepsy, has been established [203,204].

Fig. 14. The mouse model of UVB radiation-induced oxidative damage. MnSOD+/+ wild type and heterozygous MnSOD knockout mice, MnSOD+/- were studied. The UVB radiation caused nitration and subsequent inactivation of Polγ, a polymerase enzyme responsible for the replication and repair of mtDNA. With MnSOD+/- mice, the oxidative damage was significantly reduce, and was fully suppressed when mice were treated with 5 mg/kg of MnTE-2-PyP5+ ip twice daily for 2 days before radiation. Quantification of Polγ co-immunoprecipitation by anti-3-nitrotyrosine antibody in mice skin lysates in terms of arbitrary units, is shown. **P<0.01, ***P<0.001 compared with control; ###P<0.001 compared between 1 h and 24 h after UVB treatment; ^P<0.05 compared between 1 h and 24 h after UVB treatment; *=P<0.05 compared between MnSOD+/+ and MnSOD+/- mice; ^^P<0.01 compared between MnIIITE-2-PyP5+ and saline pre-treatment. Modified from ref [198].

Fig. 15. The mouse model of chronic morphine tolerance. Mn porphyrins were able to either substitute for or protect MnSOD from inactivation in a mouse whole brain homogenate when injected ip at 3 mg/kg (MnTE-2-PyP5+) and 0.1 mg/kg (MnTnHex-2-PyP5+) for 4 days along with morphine. No effect was seen on the expression of MnSOD protein. T describes tolerant group (which develops chronic morphine tolerance), and V is a vehicle group. The 30-fold increased efficacy of MnTnHex-2-PyP5+ resembles its 20-fold increased mitochondrial accumulation relative to MnTE-2-PyP5+. The higher ability of MnTnHex-2-PyP5+ to cross BBB further potentiates its effect in comparison with MnTE-2-PyP5+. Modified from ref [201].
The predominant pathological lesion underlying cerebral palsy in premature infants is thought to be the result of hypoxic–ischemic injury to the cerebral white matter; the main cell type injured is developing oligodendrocyte, OL [204]. Overexpression of MnSOD in developing OLs provides protection to mitochondrial membrane potential and reduces cell death in a mild form of cysteine deprivation, indicating glutathione as a primary defect of energy disruption [204].

In a rabbit dam uterus ischemia model, only lipophilic MnTnHex-2-PyP5+ which crosses the BBB to a 9-fold higher level and accumulates 20-fold more in mitochondria than MnTE-2-PyP5+ was successful in suppressing symptoms of cerebral palsy [163]. Both compounds were given iv to rabbit dam 30 min before and 30 min after 40 minute-long uterine ischemia. MnTnHex-2-PyP5+ was tested at 0.12 mg/kg and 1.20 mg/kg, and MnTE-2-PyP5+ at 15 mg/kg. The lower dose of MnTnHex-2-PyP5+ was more efficacious, while the higher dose carried some toxicity. In a control group, 30 kits were stillborn, 38 were hypertonic, and 36 normal out of 51 fetuses (no still born kits were found with lower dose of MnTnHex-2-PyP5+). However, when the MnTnHex-2-PyP5+ was given only during reperfusion, due to its insufficient fast accumulation in a fetal brain (as followed by MRI, the tmax ~2 h), the effects were small: 20 kits were stillborn, 14 hypertonic, and 8 healthy out of 41 fetuses [163].

### 10. Summary

We have described here in details two strategies to bring the redox-active molecule into mitochondria. Both strategies were shown successful in ameliorating mitochondrially-based oxidative stress disorders. The 1st strategy explores the use of true SOD mimics which are able to efficiently catalyze the dismutation of O$_2^-$ and accumulate in mitochondria. Such compounds belong to the class of cationic Mn(III) N-substituted pyridyl- and N,N'-disubstituted imidazolylporphyrins. Some of them have rate constants, $k_{cat}(O_2^-)$, nearly identical in magnitude to those of SOD enzymes. Liberman and Skulachev pointed to the preferred accumulation of monocationic phosphonium compounds in mitochondria. Subsequently, Murphy et al. pointed to the critical role that lipophilicity plays also. The cationic Mn porphyrin molecule combines in its structure critical features that allow it to mimic both the action and the site of mitochondrial enzyme, MnSOD: (1) redox active Mn site, (2) multiple cationic charge, and (3) four alkyl chains. The longer the alkyl chains, the higher the Mn porphyrin accumulation in mitochondria. MnTE-2-PyP5+ bears fairly short ethyl chains (Fig. 2), yet its multiple pentacationic charge compensates for its inferior lipophilicity; in turn this molecule reaches the mitochondria where it was shown to mimic MnSOD action in several different models of oxidative stress. The 2nd strategy has been the one employed in the design of MitoNOS, where redox-active quinone was linked to monocationic triphenylphosphonium ion and lipophilic alkyl chain in order to enter mitochondria. As a consequence of such elegant design, numerous Mito-derivatized redox modulators, able to reduce levels of a variety of reactive species (H$_2$O$_2$, NO, ONOO$,^-$, lipid peroxyl and alkoxyl radicals, etc) which are involved in mitochondrial dysfunction, have been reported: MitoSOD™ Red, MitoSNO, MitoSalen, Mito-Nitroxides (Mito-Tempol, Mito-CP and MitoCTP), MitoEbselen, MitoB, Mito-cToc. Among those compounds, MitoSOD™ Red bears dihydroethidium as a redox-active unit, which reacts stoichiometrically with O$_2^-$, and is thus often used as a mechanistic tool to provide evidence that O$_2^-$ has indeed been involved in a mitochondrially-based disorder. Caution needs to be exercised because modulatory effect of MitoSOD™ Red (but not SOX – dihydroethidium – in its own right) on cellular bioenergetics has recently been observed [103]. Other compounds, which were shown beneficial in reducing oxidative stress, and for which some evidence exists that they reach the mitochondria, have also been discussed.

### 11. Abbreviations

AP-1, activator protein-1; bFGF, basic fibroblast growth factor; BMP-7, bone morphogenetic protein-7; CO$_2$, carbonic acid; DMBA, 7,12-dimethylbenz (a)-anthracene; E$_{1/2}$, half-wave reduction potential; EPO, erythropoietin; HClO, hypochlorous acid; HIF-1$\alpha$, hypoxia inducible factor-1$\alpha$; ivc, intracerebroventricular; IL-1, interleukin-1, IL-6, interleukin-6; ip, intraperitoneal; iv, intravenous; MitoQ, mito-quinone; NF-$\kappa$B, nuclear factor $\kappa$B; NHE, normal hydrogen electrode; OH, hydroxyl radical; O$_2$, superoxide; ONOO$^-$, peroxynitrite; P$_{O_{2}}$, partition between n-butanol and water; $R_f$, thin-layer chromatographic retention factor that presents the ratio between the solvent and compound path in 1:1.8 = KNO$_3$(sat); $\text{H}_2\text{O}:\text{CH}_3\text{CN}$ solvent system; RO$_2$ (RO), lipid peroxyl (alkoxyl) radicals; ROS, reactive oxygen species; RS, reactive species; SAR, structure-activity relationship; sc subcutaneous; SDF-1, stromal cell derived factor-1; SOD, superoxide dismutase; Sp1, specificity protein 1; TPA,
12-O-tetradecanoylphorbol-13-acetate; UQ/UQH, ubiquinone/ubisemiquinone; VEGF, vascular endothelial growth factor; charges in the Mn\(^{n+}\) ions are omitted throughout Figure legends; MnPs, Mn(III) \(-\)alkylpyridylporphyrins; Mn\(^{n+}\) oxidized (Mn + 3 oxidation state) and Mn\(^{n+}\) reduced Mn porphyrin (Mn + 2 oxidation state), total charge 5 + and 4 + are omitted in text. BBB, blood brain barrier; MnTTP \(^+\), Mn(III) meso -tetakis(N-methylpyridinium-2-yl) porphyrin; MnT-2-PyP \(^+\), Mn(III) meso-tetakis(N-pyridinium-2-yl) porphyrin; MnTE-2-PyP \(^+\), Mn(III) meso-tetakis(N-pyridinium-2-yl) porphyrin; MnTE-2-PyP \(^+\), AEOL10113, FBC-007, Mn(III) meso -tetakis(N-ethylpyridinium-2-yl) porphyrin; MnTnHex-2-PyP \(^+\), Mn(III) meso-tetakis(N-hexylpyridinium-2-yl) porphyrin; MnT-Hex-3-PyP \(^+\), Mn(III) meso-tetakis(N-hexylpyridinium-3-yl) porphyrin; MnTnOct-2PyP \(^+\), Mn(III) meso-tetakis(N-octylpyridinium-2-yl) porphyrin; MnBrTn3-2PyP \(^+\), Mn(II) \(-\)octabromo-meso-tetakis(N-methylpyridinium-3-yl) porphyrin; MnCl2TE-2-PyP \(^+\), Mn(II) \(-\)pentachloro-meso-tetakis(N-ethylpyridinium-2-yl) porphyrin; MnTMnHex-3-PyP \(^+\), Mn(III) meso-tetakis(N-6-methoxyhexyl) pyridinium-3-yl) porphyrin; MnTnBuOE-2-PyP \(^+\) (BMX-001), Mn(III) meso-tetakis(N-2-butoxethylpyridinium-2-yl) porphyrin; MnTDE-2-ImP \(^+\) (AEOL10150), Mn(III) meso-tetakis(N, N′-diethylimidazolium-2-yl) porphyrin; MnMImP \(^+\), Mn(III) 5,10,15,15-tetraisomimidazol-2-monon(N, N′-dimethylimidazolium-2-yl)porphyrin; MnTBP \(^+\) (also MnTClP \(^+\) and AEOL10201), Mn(III) meso-tetakis(4-carboxylatophenyl) porphyrin; MnTnPyP \(^+\), manganese(III) meso-tetakis(N-methylpyridinium-4-yl) porphyrin; MnTCP, manganese meso-tetakis(ethoxycarbonyl) porphyrin; FeTET-2-PyP(OH) \(^{4-}\), Fe(III) monohydroxomo meso-tetakis(N-ethylpyridinium-2-yl) porphyrin.

Acknowledgement

We acknowledge the support of IBH general research funds Duke University’s CTS grant 1 UL 1R002412-01 from NCCR/NIH (AT, IBH, IS), NIH U19AI067798 (VZ, IBH and AT), R01 DA024074 (DS and IBH), and R01 CA 139843 (SM and DK). Authors are thankful to Irwin Fridovich for critical reading.

References


